|View printer-friendly version|
|BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients|
"We are pleased to open enrollment to
The trial is designed to enroll 200 patients with ALS, and is being conducted at six leading ALS clinical sites in the U.S. The primary outcome measure is the ALSFR-S score responder analysis. The patient population is being optimized to include the pre-specified subgroups who demonstrated superior outcomes in the NurOwn Phase 2 ALS clinical trial. Top-line data are expected in 2019. For more information, refer to www.clinicaltrials.gov, using the NCT identifier NCT03280056.
View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-phase-3-trial-of-nurown-in-als-now-open-to-canadian-patients-300620869.html